Who are RotaTeq™ experimental formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Measles Vaccine (MV), Pentavalent rotavirus vaccine, Varicella Virus Vaccine Live, Measles, mumps, rubella vaccine, Bacille Calmette-Guerin, Stamaril, Sanofi Pasteur.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rotateq-experimental-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RotaTeq™ experimental formulation — Competitive Intelligence Brief

RotaTeq™ experimental formulation (RotaTeq™ experimental formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Rotavirus structural proteins (VP4, VP7) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

RotaTeq™ experimental formulation (RotaTeq™ experimental formulation) — Merck Sharp & Dohme LLC. RotaTeq is a live attenuated rotavirus vaccine that stimulates immune responses against rotavirus to prevent gastroenteritis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RotaTeq™ experimental formulation TARGET	RotaTeq™ experimental formulation	Merck Sharp & Dohme LLC	phase 3	Live attenuated vaccine	Rotavirus structural proteins (VP4, VP7)
Measles Vaccine (MV)	Measles Vaccine (MV)	PATH	marketed	Live attenuated vaccine
Pentavalent rotavirus vaccine	Pentavalent rotavirus vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine
Varicella Virus Vaccine Live	Varicella Virus Vaccine Live	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine	Varicella-zoster virus (VZV)
Measles, mumps, rubella vaccine	Measles, mumps, rubella vaccine	PATH	marketed	Live attenuated vaccine
Bacille Calmette-Guerin	Bacille Calmette-Guerin	Urological Oncology Council of Northern Tokyo	marketed	Live attenuated vaccine / Immunotherapeutic agent
Stamaril, Sanofi Pasteur	Stamaril, Sanofi Pasteur	Epicentre	marketed	Live attenuated vaccine	Yellow fever virus (17D strain)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RotaTeq™ experimental formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/rotateq-experimental-formulation. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab